Remix Therapeutics
The Controller will lead accounting operations, ensure accurate financial reporting, and maintain a strong internal control environment for a clinical-stage biotechnology company. This role oversees the monthly close, manages a team of accounting professionals, and supports the company's transition to a public organization.
Headquarters
Watertown, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies that modulate RNA processing to address disease drivers. The company's proprietary REMaster™ platform designs small molecules that harness cellular machineries to control RNA processing and modulate expression of disease-driving mRNAs and proteins, including historically undruggable targets. Its lead program, REM-422, is a first-in-class orally available small molecule mRNA degrader targeting MYB, with programs spanning oncology and other indications of high unmet medical need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Remix Therapeutics.
67% above the average for this role
Remix Therapeutics names Mythili Koneru as chief medical officer By Investing.com
Jan 6, 2026